# Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

> **NCT07188012** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Siponuoyin Biotechnology Co Ltd** · enrollment: 9 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy (DMD)

## Interventions

- **GENETIC:** SPOT-03

## Key facts

- **NCT ID:** NCT07188012
- **Lead sponsor:** Shanghai Siponuoyin Biotechnology Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188012, "Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07188012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*